Patent Expiry

Patent/Exclusivity Expiry: HALAVEN

Other upcoming events for ABUS

Phase 3 ReadoutPhase 3 Topline: A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Phy
Patent ExpiryPatent/Exclusivity Expiry: VEMLIDY

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: HALAVEN — ABUS Patent Expiry | BioSniper